Short Interest in Gyrodyne , LLC (NASDAQ:GYRO) Expands By 38.5%

Gyrodyne , LLC (NASDAQ:GYRO) saw a large growth in short interest in the month of February. As of February 27th, there was short interest totaling 72 shares, a growth of 38.5% from the February 12th total of 52 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 179 shares, the days-to-cover ratio is presently 0.4 days. Based on an average trading volume of 179 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.0% of the shares of the company are sold short.

Gyrodyne Trading Down 9.7%

Gyrodyne stock traded down $0.85 during midday trading on Friday, reaching $7.90. The stock had a trading volume of 1,322 shares, compared to its average volume of 492. Gyrodyne has a 12 month low of $6.80 and a 12 month high of $12.00. The firm’s 50-day moving average price is $8.88 and its 200 day moving average price is $9.49.

Institutional Trading of Gyrodyne

A number of institutional investors have recently modified their holdings of GYRO. Bulldog Investors LLP bought a new position in Gyrodyne in the 3rd quarter worth approximately $601,000. Teton Advisors LLC bought a new stake in Gyrodyne during the 3rd quarter valued at $177,000. Susquehanna International Group LLP purchased a new stake in shares of Gyrodyne during the third quarter worth $142,000. Finally, Advisory Services Network LLC purchased a new stake in shares of Gyrodyne during the third quarter worth $77,000. 71.36% of the stock is currently owned by hedge funds and other institutional investors.

About Gyrodyne

Gyrodyne Company of America, Inc is a New York–based real estate investment and development firm specializing in medical office buildings and professional facilities. Listed on the NASDAQ under the ticker GYRO, the company’s principal business activity is the ownership, leasing and management of commercial properties tailored to healthcare and life sciences tenants. By focusing on outpatient diagnostic and treatment centers, clinical laboratories and related professional suites, Gyrodyne generates steady rental income and seeks to provide purpose-built environments that meet the specific needs of medical practitioners and research organizations.

The company’s core property portfolio is anchored by an approximately 87-acre campus situated in Stony Brook, Long Island.